PHAS PhaseBio Pharmaceuticals Inc.

-0.01  -0%
Previous Close 6.75
Open 6.75
Price To Book -1.42
Market Cap 165240865
Shares 24,498,275
Volume 104,175
Short Ratio
Av. Daily Volume 193,275

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b dosing of first patient announced November 27, 2018 with data due 1H 2020.
Pulmonary arterial hypertension (PAH)
Phase 2a trial to be initiated 1H 2019.
Reversal agent for ticagrelor

Latest News

  1. PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
  2. PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
  3. PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent
  4. Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
  5. PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference
  6. PhaseBio Appoints Richard A. van den Broek to Board of Directors
  7. PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
  8. Johnson & Johnson Is Selling These 2 Biotech Stocks
  9. A few minutes with... PhaseBio CEO Jonathan Mow
  10. The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
  11. The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings
  12. PhaseBio Reports Third Quarter 2018 Financial and Business Results
  13. PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
  14. PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018
  15. PhaseBio to Present at Stifel 2018 Healthcare Conference
  16. PhaseBio's IPO: What You Need To Know
  17. IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service